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Abstract 
Six novel phosphoramidate prodrugs of uridine analogues, with structural modifications 
introduced at the 6- and 2’,6-positions, has been prepared and was evaluated for selective 
antiviral activity against hepatitis C virus, as well as some other positive-stranded RNA 
viruses. An analysis of the conformational properties of the parent nucleosides was 
carried out using two-dimensional NMR spectroscopy based experiments, highlighting a 
3′-endo (North) sugar puckering preference and syn orientation. 
 
 
  
1. Introduction 
 
Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus of which the 
replication is exclusively located in membrane-associated replication complexes in the 
cytoplasm of infected cells.1 In contrast to HIV and HBV, for which the chronic infection 
is caused respectively by integration of the viral genome into the host cell DNA or the 
establishment of the viral extrachromosomal cccDNA, antiviral treatment of a chronic 
HCV infection can successfully result in a sustained virological response (SVR). In the 
past, the immunotherapeutic regimen with IFN/RBV allowed to achieve an SVR of 50% 
(genotype 1) to 70-90% (genotypes 2 and 3). Recently, SVR’s have significantly 
improved with the clinical approval of combination regimens with selective antiviral 
inhibitors (Harvoni®, Gilead; Viekira Pak®, AbbVie).    
The introduction of structural variation at multiple positions of both the base and sugar 
moieties of natural ribonucleos(t)ides has yielded numerous analogues with the potential 
to interfere with viral replication i.e. by competitive binding to the RNA-dependent RNA 
polymerase (RdRp) catalytic site and/or by termination of the growing RNA chain.4 The 
insight into the SAR of these compounds has significantly increased, for example 
allowing to conclude that the presence of a methyl group at the 2’-β-position on the ribose 
ring is an important structural element necessary to achieve good inhibitory activity on 
the HCV RNA polymerase activity without interfering with the function of host cell 
RNA-dependent polymerases (and thus less cytotoxicity).5  
A well-known concept in the development of new biologically active nucleoside 
derivatives is the importance of their conformational preference in view of their possible 
interaction with target enzymes. The introduction of a substituent at the 6-position of a 
pyrimidine base is described in the literature as giving rise to syn-conformationally 
constrained ribonucleosides, some of which have shown interesting anti-plasmodial6 and 
anti-cancer7 activities. Their scope as antivirals has largely remained uninvestigated. 
The present study was designed to evaluate the antiviral activity of a series of 6-
substituted uridine analogues, with a particular interest in combining such modification 
with the familiar 2’-C-methylribose sugar pharmacophore, and this to investigate whether 
compounds exhibiting both structural motifs would maintain the preferred conformation 
and biological profile of their parent ribonucleosides. Furthermore, a 5’-monophosphate 
prodrug strategy was pursued as many synthetic nucleotides that prove to be active in ex 
cellulo enzymatic assays, often fail to inhibit viral RNA replication in cell culture due to 
poor phosphorylation in the first rate-limiting step required for intracellular triphosphate 
activation by kinases.8 And last but not least, the introduction of aryl phosphoramidates 
to enhance the pharmacokinetic properties of nucleotides has shown fruitful in anti-HCV 
drug discovery,9 eventually leading to the FDA approval of Sufosbuvir for the treatment 
of chronic hepatitis C. 
 
2. Results and discussion 
 
2.1. Chemical synthesis 
 
Standard preparative routes were followed for the synthesis of a variety of 6-substituted 
and 2’,6-disubstituted uridine analogues, which were then used as platforms for the 
generation of an entire novel set of phosphoramidate prodrugs.  
Methyl-substituted uridine analogues 3 and 4 were readily obtained in two steps from 
commercially available 6-methyluracil and peracetylated ribofuranose or 1,2,3,5-tetra-O-
benzoyl-2’methyl-β-D-ribofuranose, respectively, under optimized Vorbruggen 
condensation reaction conditions (Scheme 1), followed by total deprotection of 
intermediates 1 and 2. In both cases, the outcome of the glycosylation step showed to be 
highly dependent on the reaction conditions, since the undesired N1,N3-bis-riboside was 
preferentially formed at room temperature. At lower temperatures, however, the exclusive 
formation of a N1-glycosidic bond rather that a N3-bond was confirmed by NOESY 
experiments, as selective irradiation of the 6-methyl group of compounds 3 and 4 showed 
a strong interaction with H-1’. These results were found to be in agreement with 1H 
correlations to C2 and C6 observed in HMBC spectra. 
 
 
 
Scheme 1. (a) BSA, sugar, TMSOTf, -20 oC to 10-15 oC, 6-48 h; (b) 7N NH3 in MeOH, 5-48 h. 
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 Initial attempts to form analogues starting from nucleobases substituted with a 6-
functional group other than methyl by a similar condensation approach were 
unsuccessful, leading to the preferential formation of a glycosidic bond at the N3-position 
(HMBC). This can be attributed to an undesired silylation reaction taking place at 6-
position, thus leading to an increased steric hindrance at the N1-position in the pyrimidine 
ring which impedes the coupling between the silylated base and the electrophilic sugar 
cation required to form the glycosidic bond.  
Thus, a literature route was pursued to access 6-modified ribouridines, which relies upon 
the initial introduction of an iodine atom at the 6-position of the base, followed by an 
addition-elimination step. As shown in Scheme 2, the hydroxyl groups at the 2’- and 3’-
positions of uridine were simultaneously protected with acetone in the presence of a 
catalytic amount of sulfuric acid, followed by conventional silylation at the 5’-position. 
The resulting protected compound 5 was then treated with LDA and iodine at low 
temperature under dry conditions to give compound 6 in 55% yield.6a Removal of the 
TBDMS and isopropylidene groups in the presence of TFA proceeded in excellent yield 
to afford 6-iodouridine 7. In addition, treatment of compound 6 with (Et)4NCN or NaN3 
in dry DMF,10 afforded the corresponding 6-cyanouridine 10 and 6-azidouridine 11 in 
moderate yields, after a deprotection step. 
   
 
Scheme 2. (a) Acetone, H2SO4, 3 h; (b) TBDMSCl, Im, dry DMF, overnight; (c) LDA, I2, AcOH, 
dry THF, 5 h; (c) 50% aq. TFA; (e) (Et)4NCN, dry DMF, overnight or NaN3, dry DMF, overnight; 
(f) 50% aq. TFA. 
 
In a similar fashion, we aimed to generate another group of compounds that incorporate 
in the sugar moiety the key feature necessary for HCV inhibitory activity. Glycosylation 
of 2’-methyl substituted ribose with uracil proceeded selectively at the N1-position to give 
14, which, after debenzoylation, underwent the same protecting steps previously 
described for uridine. However, it was found that, when compound 16 was subjected to 
the iodination reaction, no product was formed. This result was attributed to the poor 
stabilization of the anionic intermediate forming at the 6-position under the applied 
reaction conditions. Steric factors linked to the presence of the 2’-methyl group on the 
sugar ring might be accountable for the absence of the formation of mixed aggregate 
derived stabilizing the intermediate species.11  
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Scheme 3. (a) BSA, sugar, TMSOTf, -20 oC to 70 oC, 3 h; (b) 7N NH3 in MeOH, 5-48 h; (c) 
Acetone, H2SO4, 3 h; (d) TBDMSCl, Im, dry DMF, overnight; (e) BSA, sugar, SnCl4, CH2Cl2, rt; 
(f) 7N NH3 in MeOH; (g) (i) TBDMSCl, Im, dry DMF, overnight, (ii) (Et)4 NCN, dry DMF, 
overnight, (iii) TBAF in THF. 
 
An alternative route, however, provided an additional 2’,6-modified substrate, compound 
18. The formation of 2’-methyl-5-iodouridine 17 was readily realized as reported in the 
literature12, followed by an addition-elimination reaction which converted compound 17 
to 2’-methyl-6-cyanouridine 18 in 89% yield after a final deprotection step using TBAF.13 
The presence of the new chemical bond C6-C7 (CSp2-CSp3) was confirmed by HMBC 
correlation. 
 
The substitution of the phosphate function with an amino acid ester residue and a 
lipophilic aromatic group to mask the negative charge allows hepatic delivery of higher 
concentrations of monophosphate nucleosides, which are then liberated following an 
intracellular cascade of metabolic steps and further converted into their active 
triphosphate forms. The conversion of all of the prepared nucleosides to their 
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corresponding 5’-phosphoramidates was achieved by a common methodology. The 
phosphoramidating reagent was readily prepared by reacting alanine isopropyl ester 
hydrochloride and phenyl dichlorophosphate in the presence of triethylamine at low 
temperature. Addition of the obtained reagent mixture for each of the modified 
nucleosides provided the relative phosphoramidates as diastereomeric mixtures, with 
moderate to good yields. 
 
 
Scheme 4. (a) (i) PhOP(O)Cl2, L-Alanine isopropyl ester hydrochloride, dry CH3CN, -40 oC, 
TEA, (ii) Nucleoside, N-methylimidazole, 5 h. 
 
2.2. Conformational analysis of 2’6-dimethyluridine and 2’-methyl-6-cyanouridine 
 
Subsequently, the predominant conformation of unprecedented 2’,6-disubstituted 
analogues 4 and 18 in solution was determined by NMR spectroscopy techniques. An 
anti-relationship across the glycosidic bond is common in most pyrimidine nucleosides 
as a result of repulsive interactions between the sugar ring and the carbonyl group at the 
2-position. Nevertheless, the insertion of a bulky substituent at the 6-position sterically 
restrains the molecule into a syn-conformation. We were interested in studying the effect 
played by the additional presence of a methyl group at the 2’-beta-position on both the 
glycosidic bond orientation and sugar puckering. 
Although an infinite number of conformations is theoretically possible, the pucker 
position of five-membered rings of nucleosides in the pseudorotation cycle is commonly 
confined to either of two antipodal regions, C3′-endo or “North” and C2′-endo or 
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“South”.14 An estimated ratio of North and South conformers in solution can be 
determined on the basis of the values of vicinal homonuclear coupling constants,15 and in 
our specific case exclusively from the coupling between H3’ and H4’ protons.  
For compound 4, a 3JH3’-H4’ = 9.06 Hz was measured in D2O, which is indicative for a 
predominant North-type sugar conformation,16 further corroborated by the presence of a 
significant NOE enhancement between 2'-OH and H4' and the absence of any interaction 
between 2'-Me and H5' protons (Figure 1). For comparison, the conformational analysis 
was also applied to 6-methyluridine 3 and results were consistent with literature report.7 
 
 
 
Figure 1. NOESY spectra for 6-dimethyluridine 3 and 2’,6-dimethyluridine 4, run in DMSO-d6 
on Bruker Avance II 500 MHz spectrometer with a TXI HCP probe.  
 
The 3JH3’-H4’ values measured at five different temperatures indicates that compound 4 
does not undergo a significant temperature dependent conformational change, as shown 
in Table 1. The percentage of preferred C3′-endo ring conformer was obtained by 
performing a pseudorotational analysis with the aid of a Matlab interface.17 
 
Table 1. Pseudorotational analysis data for compound 4. 
T oC peak 1 peak 1 3JH3’-H4’ % N-
conformer 
5 2439.1682 2430.0462 9.122 92.24 
10 2474.9359 2465.814 9.1219 92.24 
15 2510.2236 2501.1616 9.062 91.36 
20 2544.1909 2535.129 9.0619 91.36 
25 2577.1981 2568.1361 9.062 91.36 
 
The determination of the prevalent orientation state, derived from the relative positions 
of sugar and base around the glycosidic bond, was based upon the values of 3JH1’C6 and 
3JH1’C2, the combination of which represents a direct correlation to the syn- or anti-range 
for the glycosidic torsion angle χ.18 Thus, in a 1D 13C NMR spectrum where no 1H 
decoupling was applied during signal detection, compound 4 exhibited 3JH1’C6 = 4.78 Hz 
and 3JH1’C2 = 6.49 Hz at 600 MHz in D2O. Since 
3JH1’C2 > 
3JH1’C6, which allows to 
concluded that the glycosidic torsion angle χ is in the syn domain. 
The observed syn-relationship of the nucleobase relative to the sugar ring was supported 
by analysis of NOE interactions. Selective irradiation of the group at the 6-position 
showed the presence of strong cross peaks between R-6 and H-1’ in all compounds, whilst 
any correlation of R-6 to H5’ and H5” was absent. 
 
 
3. Biological evaluation 
 
Initially, the synthetized nucleoside phosphoramidates 19-24 were evaluated for selective 
antiviral activity against the following viruses: hepatitis C virus (type 1b, Con1 strain) in 
the Huh 5-2 replicon system. No selective antiviral activity could be observed. Because 
of the high conservation of the catalytic amino acid motifs across RNA-dependent RNA 
polymerases of positive-strand RNA viruses,19 the compounds were subsequently also 
evaluated against chikungunya virus and also various species belonging to the genus 
Enteroviruses, for instance Coxsackie virus (type B3, Nancy strain) in Vero cells (subtype 
A), Coxsackievirus (type B4, E2 Edwards strain) in Vero cells (subtype A), Poliovirus 
(type 1, Sabin strain) in BGM cells, enterovirus 71, and rhinovirus (type 14) in Hela cells 
(subtype Rh). Unfortunately, no selective antiviral activity could be observed either.  
 
4. Conclusion 
A new set of phosphoramidate nucleosides, derived from 6- and 2’,6-modified uridines, 
were prepared but found to be devoid of selective antiviral activity on the replication of 
several single-stranded, positive-sense RNA viruses. Spectroscopic analysis of the 
conformational properties of the parent nucleosides showed a syn/N preference, which is 
incompatible with recognition by viral replication enzymes and as such provides an 
explanation for the lack of antiviral activity.  
 
  
5. Experimental section 
 
5.1 General 
NMR spectra were recorded on Bruker Avance I 300 MHz (BBI probe), Avance II 500 
MHz (TXI HCP probe) and 600 MHz (TCI HCN cryoprobe) spectrometers using a TXI 
HCP probe. Chemical shifts (δ) are expressed in parts per million (ppm). 1H and 13C 
NMR chemical shifts are referenced relative to TMS (δ = 0.00 ppm). Mass spectra were 
acquired on a quadrupole orthogonal acceleration time-of-flight mass spectrometer 
(Synapt G2 HDMS, Waters, Milford, MA). Samples were infused at 3uL/min and spectra 
were obtained in positive (or negative) ionization mode with a resolution of 15000 
(FWHM) using leucine enkephalin as lock mass. Thin-layer chromatography (TLC) was 
performed on Alugram silica gel UV254 mesh 60, 0.20 mm (Macherey-Nagel).  
 
5.1. 1-(2’,3’,5’-Tri-O-acetyl-β-D-ribofuranosyl)-6-methyluracil (1). 
To a solution of 6-methyluracil (604.0 mg, 4.80 mmol) in dry CH3CN (10 mL), was added 
N,O-bistrimethylsilylacetamide (2.4 mL, 14.0 mmol) and the mixture was stirred for 20 
min at room temperature. To this mixture, a solution of 1,2,3,5-tetra-O-acetyl-β-D-
ribofuranose (1.27 g, 4.00 mmol) in dry CH3CN (15 mL) was then added. After cooling 
to -20 °C, TMSOTf (2.4 mL, 4.4 mmol) was added and the reaction mixture was allowed 
to warm slowly to 15-20 °C and stirred for 6 h. The mixture was then poured into CH2Cl2 
and washed with saturated aq. NaHCO3. The water layer was extracted with CH2Cl2. The 
organic extracts were combined and dried over Na2SO4, filtered and evaporated in vacuo. 
The crude residue was purified by column chromatography (CH2Cl2/MeOH 49:1) on 
silica gel to give product 1 (1.50 g) as an anomeric mixture. The β-anomer was isolated 
in 81% yield (1.24 g) and the α-anomer in 11% yield (168.0 mg). The undesired N1,N3-
bis-riboside was isolated in 11.2 % yield (173.0 mg). All products were oils. Data for 1 : 
1H-NMR (600MHz, DMSO-d6): δ 11.39 (s, 1H, NH), 5.57 (d, 1H, J = 2.2 Hz, H-2’), 5.57-
5.55 (m, 2H, H-5 and H-1’), 5.42 (dd, 1H, J = 2.2 Hz and J = 6.6 Hz, H-3’), 4.32 (m, 1H, 
H-5’), 4.15-4.12 (m, 1H, H-4’), 4.03 (m, 1H, H-5’’), 2.25 (s, 3H, 6-CH3), 2.11 (s, 3H, 
CH3), 2.10 (s, 3H, CH3), 2.09 (s, 3H, CH3); 
13C-NMR (150MHz, DMSO-d6): δ 170.2 (2 
x CO), 169.5 (CO), 162.4 (4-C), 153.0 (2-C), 150.6 (6-C), 102.5 (5-CH), 90.1 (1’-CH), 
78.2 (4’-CH), 73.0 (2’-CH), 69.7 (3’-CH), 62.9 (5’-CH2), 20.6 (CH3), 20.5 (CH3), 20.3 
(CH3), 19.5 (6-CH3); HRMS for C16H20N2O9 [M–H]
- Calc.: 383.1095, found: 383.1103. 
 
5.2. 1-(2’,3’,5’-Tri-O-benzoyl-2’-methyl-β-D-ribofuranosyl)-6-methyluracil (2). 
 
To a solution of 6-methyluracil (302.0 mg, 2.40 mmol) in dry CH3CN (5 mL), was added 
N,O-bistrimethylsilylacetamide (1.18 mL, 7.00 mmol) and the mixture was stirred for 20 
min at room temperature. To this mixture, a solution of 1,2,3,5-tetra-O-benzoyl-2’-
methyl-β-D-ribofuranose (1.16 g, 2.00 mmol) in dry CH3CN (10 mL) was added, 
followed by dropwise addition of TMSOTf (1.4 mL) at -20 °C. The reaction mixture was 
then allowed to warm slowly to 10-15 °C and stirred for 6 h. The mixture was then poured 
into CH2Cl2 and washed with saturated aq. NaHCO3. The organic layer was combined, 
dried over Na2SO4 and filtered. After removal of all the volatiles, the residue was purified 
by column chromatography (hexane/ethyl acetate 3:13:2), to give product 2 (1.08 g) as 
an oil in 88.5% yield. The undesired N1,N3-bis-riboside (66.0 mg) was obtained as an oil 
in 5.7% yield. 1H-NMR (300MHz, DMSO-d6): δ 11.56 (s, 1H, 3-NH), 8.07–7.35 (m, 15H, 
aromatic), 6.34 (s, 1H, H-1’), 6.31 (d, 1H, J = 8.7 Hz, 3’- H), 5.66 (s, 1H, H-5), 4.73-4.66 
(m, 1H, H-4’), 4.61–4.59 (m, 2H, H-5’), 2.39 (s, 3H, 6-CH3), 1.76 (s, 3H, 2’-CH3); 
13C-
NMR (75MHz, DMSO-d6): δ 165.6 (5’’-C=O), 165.1 (2’’-C=O), 164.9 (3’’-C=O), 162.4 
(4-C), 154.1 (2-C), 150.9 (6-C), 134.0–128.7 (15 x C-aromatic), 102.9 (5-CH), 91.3 (1’-
CH), 88.0 (4’-CH), 77.4 (2’-CH), 77.1 (3’-CH), 64.5 (5’-CH2), 19.7 (7-CH3), 18.1 (6’-
CH3); HRMS for C32H28N2O9 [M+H]
+ Calc.:585.1867, found: 585.1897. 
 
5.3. 6-Methyluridine (3). 
 
A dried 50 mL round-bottomed flask was charged with 1 (550.0 mg, 1.43 mmol) and 20 
mL of a 7N solution of NH3 in MeOH was then added at 0 °C. The reaction was allowed 
to warm slowly to room temperature and stirred for 5 h to give a yellow solution. The 
solvent was then removed in vacuo and the resulting residue was purified by column 
chromatography (CH2Cl2/ MeOH 9:1) on silica gel to give product 3 (268 mg) as a white 
solid in 75% yield. UV λmax (MeOH) = 269 nm (ε = 5 179 mol
-1 cm-1); 1H-NMR (500MHz, 
DMSO-d6): δ 11.10 (s, 1H, NH), 6.03 (d, 1H, J = 3.7 Hz, H-1’), 5.45 (s, 1H, H-5), 4.99 
(d, 1H, J = 4.8 Hz, OH-2’), 4.82 (d, 1H, J = 6.3 Hz, OH-3’), 4.55 (t, 1H, J = 5.8 Hz, H-
2’), 4.46 (d, 1H, J = 5.35 Hz, OH-5’), 4.08 (q, 1H, J = 6.0 Hz, H-3’), 3.69-3.55 (m, 2H, 
H-5’), 3.68-3.65 (m, 1H, H-4’), 2.02 (s, 3H, 6-CH3); 
13C-NMR (125MHz, DMSO-d6): δ 
162.9 (4-C), 152.4 (2-C), 151.1 (6-C), 98.7 (5-CH), 87.3 (1’-CH), 84.4 (4’-CH), 71.0 (2’-
CH), 70.3 (3’-CH), 62.5 (5’-CH2), 18.2 (7-CH3); HRMS for C10H14N2O6 [M+H]
+ Calc.: 
259.0924, found: 259.0931. 
 
5.4. 2’,6-Dimethyluridine (4). 
A dried 50 mL round-bottomed flask was charged with 2 (1.20 g, 4.41 mmol) and 20 mL 
of a 7N solution of NH3 in MeOH was then added at 0 °C. The reaction was allowed to 
warm slowly to room temperature and stirred for two days. The solvent was then removed 
in vacuo and the residue was purified by column chromatography (CH2Cl2/MeOH 100:7) 
on silica gel to give product 4 (459.0 mg) as a white solid in 84% yield. 1H-NMR 
(300MHz, D2O): δ 5.67 (s, 2H, H-1’ and H-5), 4.22-4.19 (m, 1H, H-3’), 3.89 - 3.76 (m, 
3H, H-4’ and H-5’), 2.30 (s, 3H, 6-CH3), 1.21 (s, 3H, 2’-CH3); 
13C-NMR (75 MHz, D2O): 
δ 165.1 (4-CO), 155.6 (2-CO), 150.7 (5-CH), 102.3 (5-CH), 94.3 (1’-CH), 82.4 (4’-CH), 
79.0 (2’-CH), 73.9 (3’-CH), 61.4 (5’-CH2), 20.0 (7-CH3), 19.0 ( 6’-CH3). MS for 
C32H28N2O9 [M+H]
+ Calcd.: 273.1089, found: 273.1089. 
 
5.5. 6-Cyanouridine (10). 
 
A dried 100 mL, round-bottomed flask was charged with 5-O-(tert-butyldimethylsilyl)-
6-iodo-2’,3’-O-isopropylideneuridine 6 (200.0 mg, 0.38 mmol) in anhydrous 
dimethylformamide (4 mL) and then (Et)4NCN (150.0 mg, 1.00 mmol) was added at room 
temperature. The reaction mixture was stirred overnight, poured into water (20 mL) and 
extracted with EtOAc (100 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. The residue was treated with 50% aq. TFA (10 mL) at 0 oC and 
then stirred at room temperature overnight in the dark. The solvent was evaporated and 
the crude residue was purified by column chromatography (MeOH/CH2Cl2, 10:100) on 
silica gel to give product 10 as a brown solid (50.0 mg) in 48% yield. 1H-NMR (300MHz, 
D2O): δ 6.66 (s, 1H, H-5), 5.97 (d, 1H, J = 4.56 Hz, H-1’), 4.73 (q, 1H, J = 4.59, 6.6 Hz, 
H-2’), 4.34 (t, 1H, J = 6.6 Hz, H-3’), 4.07-4.01 (m, 1H, H-4’), 3.95-3.81 (m, 2H, H-5’); 
13C-NMR (75MHz, D2O): δ 162.7 (4-C), 149.7 (2-C), 126.8 (7-CN) 114.1 (6-C), 110.7 
(5-CH), 92.3 (1’-CH), 84.0 (4’-CH), 71.4 (2’-CH), 68.5 (3’-CH), 60.8 (5’-CH2). 
 
5.6. 6-Azidouridine (11).  
 
5’-O-(tert-Butyldimethylsilyl)-6-iodo-2’,3’-O-isopropylideneuridine 6 (300.0 g, 0.57 
mmol) in anhydrous DMF (3.4 mL) was treated with sodium azide (60.0 mg, 0.9 mmol). 
The reaction mixture was stirred overnight at room temperature, concentrated, and 
redissolved in EtOAc (30 mL). The organic layer was washed with water (20 mL), brine 
(20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was then 
treated with 50% aq. TFA (10 mL) at 0 oC and stirred at room temperature overnight in 
the dark. The solvent was evaporated under reduced pressure and the crude product was 
purified by column chromatography (MeOH/CH2Cl2, 10:100) on silica gel to give product 
11 as a yellow solid (146 mg, 90%). 1H-NMR (300MHz, D2O): δ 5.97 (d, 1H, J = 3.51 
Hz, H-1’), 5.63 (s, 1H, H-5), 4.65 (q, 1H, J = 3.6 Hz, H-2’), 4.32 (t, 1H, J = 6.69 Hz, H-
3’), 3.85-3.79 (m, 2H, H-5’), 3.70-3.64 (m, 1H, H-4’); 13C-NMR (75MHz, D2O): δ 163.9 
(4-C), 153.4 (2-C), 150.1 (6-C), 89.6 (5-CH), 88.3 (1’-CH), 83.3 (4’-CH), 71.3 (2’-CH), 
68.8 (3’-CH), 61.1 (5’-CH2). 
 
5.7. 1-(2,3,5-Tri-O-benzoyl-2’-methyl-β-D-ribofuranosyl)-uridine (14). 
 
To a solution of uracil 12 (250.0 mg, 2.20 mmol) in dry CH3CN (5 mL), was added N,O-
bistrimethylsilylacetamide (1.18 mL, 7.00 mmol) and the mixture was stirred for 20 min 
at room temperature. To this mixture, a solution of 1,2,3,5-tetra-O-benzoyl-2’-methyl-β-
D-ribofuranosyl (1.16 g, 2.00 mmol) in dry CH3CN (10 mL) was added. After cooling to 
-20 ˚C, TMSOTf (1.4 mL) was added and the reaction mixture was allowed to warm 
slowly to room temperature and then stirred at 70 °C for 2 h. The mixture was then poured 
into ethyl acetate and washed with saturated aq. NaHCO3. The water layer was again 
extracted with ethyl acetate. The organic extracts were combined, dried over Na2SO4 and 
filtered. After removal of all the volatiles in vacuo, the residue was purified by column 
chromatography (CH2Cl2/ MeOH 49:1) on silica gel to give product 14 (983.0 mg) as an 
anomeric mixture. The β-anomer (946.0 mg) was isolated as an oil in 75% yield. 1H-
NMR (300MHz, DMSO-d6): δ 9.7 (s, 1H, 3-NH), 8.20-7.26 (m, 16H, H-6 and 3 x 
aromatic), 6.55 (s, 1H, H-1’), 5.79 (d, 1H, J = 5.3 Hz, H-3’), 5.75 (d, 1H, J = 8.19 Hz, H-
5), 4.67-4.63 (m, 1H, 4’- H), 4.93-4.80 (m, 2H, 2H-5’), 1.78 (s, 3H, CH3); 
13C-NMR 
(75MHz, DMSO-d6): δ 165.9 (2’’-C=O), 164.97 and 164.94 (2’’ and 3’’-C=O), 162.8 (4-
C), 149.7 (2-C), 140.6 (6-C), 133.32-128.09 (aromatic), 102.1 (5-CH), 84.2 (1’-CH), 80.1 
(4’-CH), 75.2 (2’-CH), 63.0 (3’-CH), 60.1 (5’-CH2), 17.7 (CH3); HRMS for C31H26N2O9 
[M+Na]+ Calc.: 593.1530, found: 593.1541. 
 5.8. 2’-Methyluridine (15). 
 
A dried 50 mL round-bottomed flask was charged with 14 (3.00 g, 5.26 mmol) and 50mL 
of a 7N solution of NH3 in MeOH was then added at 0 
oC. The reaction was stirred at 
room temperature for 48 h. The solvent was then removed in vacuo and the residue was 
purified by column chromatography (ethyl acetate/ MeOH 100:5100:8) on silica gel to 
give product 15 (1.19 g) as a white solid in 88% yield. 1H-NMR (300MHz, DMSO-d6): 
δ 11.34 (s, 1H, 3-NH), 8.05 (d, 1H, J = 8.07 Hz, H-6), 5.80 (s, 1H, H-1’), 5.61 (d, 1H, J 
= 8.07 Hz, H-5), ), 5.18 (d, 2H, J = 4.08 Hz, H-3’, OH-3’), 5.10 (s, 1H, OH-2’), 4.06-3.59 
(m, 4H, 2H-5’, H-4’, OH-5’), 1.01 (s, 3H, CH3); 
13C-NMR (75MHz, DMSO-d6): δ 163.1 
(4-C), 150.8 (2-C), 140.5 (6-C), 101.5 (5-CH), 91.1 (1’-CH), 82.3 (4’-CH), 78.4 (2’-CH), 
71.7 (3’-CH), 58.8 (5’-CH2), 19.93 (CH3); HRMS for C10H14N2O6 [M+H]
+ Calcd.: 
259.0924, found: 259.0929. 
 
5.9. 2’-Methyl-6-cyanouridine (18). 
 
A dried 100 mL, round-bottomed flask was charged with 2’,3’,5’-tri-O-tert-
butyldimethylsilyl-5-iodo-uridine 17 (200.0 mg, 0.275 mmol) in anhydrous 
dimethylformamide (4 mL) and then (Et)4NCN (75.0 mg, 0.5 mmol) was added at room 
temperature. The reaction mixture was stirred overnight, it was then poured into NaHCO3 
(20 mL) and extracted with EtOAc (100 mL). The organic layer was dried over Na2SO4 
and concentrated in vacuo. The residue was treated with TBAF in THF (3 mL) at room 
temperature overnight. The solvent was evaporated and the crude residue was purified by 
column chromatography (MeOH/CH2Cl2, 10:100) on silica gel to give product 18 as a 
brown solid (69 mg, 89%). 1H-NMR (300 MHz, MeOD): δ 6.47 (s, 1H, H-5), 5.97 (s, 1H, 
H-1’), 4.03 (br s, 1H, H-3’), 3.95-3.91 (m, 2H, H-5’, H-5’’), 3.89-3.79 (m, 1H, H-4’), 
1.26 (s, 3H, CH3); 
13C-NMR (75MHz, MeOD): δ 161.2 (4-C), 149.0 (2-C), 126.7 (7-CN) 
113.1 (6-C), 111.2 (5-CH), 96.8 (1’-CH), 83.4 (4’-CH), 77.7 (2’-CH), 74.0 (3’-CH), 61.4 
(5’-CH2), 13.9 (2’-CH3). HRMS for C11H13N3O6 [M+Na
+] Calcd.: 306.0696, found: 
306.0698. 
 
 
5.10. General procedure for phosphoramidates synthesis 
 
A dried 50 mL, round-bottomed flask was charged with phosphate dichloride phenol (1 
mmol) and alanine isopropyl hydrochloric ester (1 mmol) in dry CH3CN under inert 
atmosphere. After cooling to -40 oC, Et3N (2 mmol) was added dropwise and stirred 
overnight. A portion of this solution was then removed under inert atmosphere and added 
to another round-bottomed flask containing the relevant nucleoside (0.35 mmol). The 
mixture was stirred until complete solubilization, then 1-methylimidazole (2 mmol) was 
added dropwise over 5 min and the stirring was continued for 3 h. The solvent was then 
removed in vacuo and the residue was purified by column chromatography (DCM/ 
ethanol/pyridine (50/3/0.2) on silica gel. 
 
5.10.1. (2S)-Isopropyl 2-(2’R,3’R,4’R) (((3’,4’-dihydroxy-5-(6-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-
)methoxy)(phenoxy)phosphorylamino)propanoate (19) 
 
Yellow oil (54.1 mg, 60% yield). 1H-NMR (300MHz, DMSO-d6): δ 11.24 (s, 1H, NH), 
7.34-7.17 (m, 10H, aromatics), 5.91 (d, 1H, H-1’), 5.57 (s, 1H, H-5), 5.44 (s, 1H, OH-2’), 
5.33 (s, 1H, OH-3’), 5.12 (d, 1H, J = 6.6 Hz, H-2’), 4.87-4.81 (m, 1H, H from alanine), 
4.22-4.12 (m, 1H, H-3’), 3.91-3.88 (m, 1H, H-4’), 3.76-3.70 (m, 2H, H-5’), 2.24 (s, 3H, 
7-CH3); 
13C-NMR (75MHz, CDCl3): δ 172.9 (=CO), 162.6 ( 4=CO), 152.7 (2=CO), 150.3 
(5-C sp
2), 102.6 (6-CH), 138.3-119.8 (aromatics), 92.9 (1’-CH), 82.0 (4’-CH), 72.5 (2’-
CH), 70.14 (3’-CH), 69.4 (5’-CH2), 69.4 (CH), 49.9 (CH), 31.6 (CH3), 21.3 (CH3), 21.2 
(CH3), 20.2 (7-CH3). 
31P-NMR (121MHz, DMSO-d6): δ 3.55; HRMS for 
C22H30N3O10P[M+H]
+ Calcd.: 528.1741, found: 528.1754. 
 
 
5.10.2. (2S)-Isopropyl 2-(2’R,3’R,4’R)(((3',4'-dihydroxy-2'-methyl-5-(6-methyl-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-
yl)methoxy)(phenoxy)phosphorylamino)propanoate (20) 
 
Yellow oil (52.3 mg, 55% yield). 1H-NMR (500MHz, DMSO-d6): δ 11.19 (s, 1H, 3-NH), 
7.32-7.09 (m, 5H, aromatic), 5.47 (s, 1H, H-1’), 5.55 (s, 1H, H-5), 5.12 (d, 1H, OH-2’), 
4.92 (s, 1H, OH-3’), 4.89-4.80 (m, 1H, 1H), 4.48 (t, 1H, J = 5.0 Hz, H-3’), 4.07 (t, 1H, J 
= 5.1 Hz H-4’), 3.86-3.62 (m, 3H, 2H-5’overlapped with 1H, CH), 2.25 (s, 3H, 6-CH3), 
1.23 (s, 6H, 2x CH3), 1.16 (d, 3H, J
  = 6.15 Hz, CH3), 1.09 (s, 3H, 2’-CH3); 
13C-NMR 
(125MHz, DMSO-d6): δ 173.4 (CO), 162.5 (4=CO), 153.5 (2=CO), 150.4 (5-CH), 129.3-
120.6 (aromatics), 102.3 (6-CH), 94.9 (1’-CH), 82.1 (4’-CH), 77.9 (2’-CH), 74.9 (3’-CH), 
68.8 (5’-CH), 67.8 (CH), 49.9 (CH), 29.3 (CH3), 20.5 (7-CH3), 20.5 (CH3), 20.4 (CH3), 
13.9 (6’-CH3). 
31P-NMR (200MHz, DMSO-d6): δ 3.75; HRMS for C23H32N3O10P[M+H]
+ 
Calcd.: 542.1897, found: 542.1897. 
 
5.10.3. (2S)-Isopropyl 2-(2’R,3’R,4’R) (((3’,4’-dihydroxy-5-(6-iodo-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-
yl)methoxy)(phenoxy)phosphorylamino)propanoate (21) 
 
Yellow oil (50.3 mg, 39% yield). 1H-NMR (300MHz, DMSO-d6): δ 11.54 (s, 1H, NH), 
7.65-7.15 (m, 10H, aromatics), 6.35 (s, 1H, H-5), 5.76 (d, 1H, J = 2.31 Hz, H-1’), 5.35 (t, 
1H, J = 4.38 Hz), 5.16 (d, 1H, J = 6.81 Hz), 4.88-4.80 (m, 1H), 4.51 (s, 1H), 4.51-3.72 
(m, 5H), 1.23-1.13 (m, 18H, 6 x CH3); 
13C-NMR (125MHz, DMSO-d6): δ 172.7 (=CO), 
161.6 (4=CO), 150.8 (2=CO), 147.3 (5-C sp
2), 132.1-120.2 (aromatics), 118.4 (6-C), 115.4 
(1’-CH), 82.4 (4’-CH), 71.6 (2’-CH), 69.8 (3’-CH), 68.0 (5’-CH2), 49.9 (CH), 49.8 (CH), 
29.1 (CH3), 21.5 (CH3), 21.4 (CH3); 
31P-NMR (121MHz, CDCl3): δ 2.86 and 2.75; HRMS 
for C21H27IN3O10P[M+H]
+Calcd.: 640.0553, found: 640.0552.  
 
5.10.4. (2S)-Isopropyl 2-(2’R,3’R,4’R) ((((5-(6-cyano-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)(phenoxy)phosphorylamino)propanoate (22) 
 
Yellow oil (39.5 mg, 42% yield). 1H-NMR (300MHz, DMSO-d6): δ 9.51 (s, 1H, NH), 
7.30-7.16 (m, 10H, aromatics), 6.43 (s, 1H, H-5), 5.91 (s, 1H, H-1’), 5.30 (s, 1H), 5.05-
4.94 (m, 2H), 4.44-3.96 (m, 5H), 3.94-3.59 (m, 4H), 1.23 (s, 9H, 3 x CH3); 
13C-NMR 
(125MHz, CDCl3): δ 173.1 (=CO), 150.5 (2=CO), 160.8 (4=CO), 147.3 (5-Csp
2), 129.8-
129.6 (aromatic), 125.1 (6-CN), 117.1 (6-C), 113.7 (1’-CH), 82.5 (4’-CH), 73.5 (2’-CH), 
70.0 (3’-CH), 69.5 (5’-CH2), 66.5 (CH), 50.2 (CH), 29.7 (CH3), 21.7 (CH3), 21.6 (CH3); 
31P-NMR (121MHz, DMSO-d6): δ 2.91 and 2.81; HRMS for C22H27N4O10P[M+H]
+ 
calcd.:575.1513; found: 575.1516. 
 
5.10.5. (2S)-Isopropyl 2-(2’R,3’R,4’R) (((5-(6-azido-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methoxy)(phenoxy)phosphorylamino)propanoate (23) 
 
Pale yellow oil (42.8 mg, 22% yield). 1H-NMR (500MHz, CDCl3): δ 9.50 (s, 1H, NH), 
7.35-7.17 (m, 5H, aromatics), 5.93 (s, 1H, H-5), 5.50-5.49 (d, J = 4.05 Hz, 1H, H-1’), 
5.02-4.98 (m, 1H), 4.75-4.74 (d, J = 7.25 Hz, 1H), 4.67-4.65, (d, J = 10.5 Hz , 1H), 4.42-
4.40 (m, 1H), 4.32 (s, 1H), 4.16-4.13 (m, 1H), 4.94-4.02 (m, 1H), 1.22-1.24 (m, 9H, 3x 
CH3); 
13C-NMR (200MHz, CDCl3): δ 173.2 (=CO), 161.5 (4=CO), 152.3 (2=CO), 150.6 
(5-C sp
2), 149.5 (2=CO), 129.7 (aromatic), 125.0 (aromatic), 120.2 (aromatic), 120.1 
(aromatic), 91.0 (6-C), 88.8 (1’-CH), 82.3 (4’-CH), 73.1 (2’-CH), 70.5 (3’-CH), 69.5 (5’-
CH2), 66.7 (CH), 63.1 (CH), 50.3 (CH), 29.7 (CH3), 21.6 (CH3), 21.6 (CH3); 
31P-NMR 
(75MHz, CDCl3): δ 2.99 and 2.84; HRMS for C21H27N6O10P1 [M+H]
+ calcd.:555.1598, 
found: 555.1595.  
 
 
5.10.6. (2S)-Isopropyl 2-(2’R,3’R,4’R)(((3',4'-dihydroxy-2'-methyl-5-(6-cyano-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-
yl)methoxy)(phenoxy)phosphorylamino)propanoate (24) 
 
Yellow oil (33.0 mg, 60% yield). 1H-NMR (500 MHz, DMSO): δ 10.36 (s, 1H, H-3), 
7.35-7.11 (m, 5H, aromatic), 6.31 (s, 1H, H-5), 5.96 (s, 1H, H-1’), 5.03-4.95 (q, 1H, J = 
6.24, H amino ester), 4.54-4.43 (m, 3H), 4.35-4.20 (m, 2H), 4.18-4.11 (m, 2H), 1.37-1.20 
(m, 12H, 4 x -CH3); 
13C-NMR (125MHz, CDCl3): δ 172.8 (-CO), 160.0 (4-C), 150.3 (2-
C), 148.5 (5-C sp
2), 129.4 (aromatic), 124.8 (aromatic), 129.7-119.9 (aromatic), 125.9 (7-
CN), 113.1 (6-C), 110.6 (5-CH), 97.5 (1’-CH), 82.1 (4’-CH), 74.5 (2’-CH), 69.9 (3’-CH), 
66.7 (-CH), 64.8 (5’-CH2), 50.0 (CH), 29.4 (CH3), 21.3 (CH3), 21.3 (CH3), 13.8 (CH3);
 
31P-NMR (75 MHz, DMSO-d6): δ 3.05 and 2.79; HRMS for C23H29N4O10P1 [M+Na
 +] 
Calcd.: 575.1513, found: 575.1516.  
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